<DOC>
	<DOC>NCT02649465</DOC>
	<brief_summary>1. Objectives 1. Which organ and how does SGLT2 inhibitor alter insulin sensitivity? 2. How does SGLT2 inhibitor increase glucagon levels and hepatic glucose production?</brief_summary>
	<brief_title>SGLT2 Inhibitor Versus Sulfonylurea on Type 2 Diabetes With NAFLD</brief_title>
	<detailed_description>2. Clinical hypothesis 1. SGLT2 inhibitor ameliorates fatty liver and obesity. 2. SGLT2 inhibitor stimulates sympathetic activity. 3. SGLT2 inhibitor increases glucagon secretion. 4. SGLT2 inhibitor enhances lipolysis and hepatic glucose production.</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<criteria>1. The biopsy consistent with the diagnosis of NAFLD 2. Type 2 diabetes, HbA1c &gt;=7.0% 1. Hepatic virus infections (hepatitis C virus RNAPCRpositive, hepatitis B and C, cytomegalovirus and EpsteinBarr virus), autoimmune hepatitis, primary biliary cirrhosis, sclerosing cholangitis, haemochromatosis, alpha 1antitrypsin deficiency, Wilson's disease, history of parenteral nutrition and use of drugs known to induce steatosis (e.g. valproate, amiodarone and prednisone) or hepatic injury caused by substance abuse and/or the current or past consumption of more than 20 g of alcohol daily 2. Hypersensitivity to or contraindication of glimepiride and tofogliflozin 3. None type 2 diabetes 4. Poorly controlled diabetes (states of hyperglycemic hyperosmolar syndrome and diabetic ketoacidosis) 5. Repeated episodes of unexplained hypoglycemia, as defined by a FPG &lt;60 mg/dl, with or without symptoms of hypoglycemia 6. Concomitant infection or planned surgery 7. Poorly controlled hypertension (systolic blood pressure &gt;160 mmHg, or diastolic blood pressure &gt;100 mmHg) 8. Severe retinopathy 9. Malignancy on an active therapeutic regimen or malignancy without complete remission or cure 10. Severe health problems not suitable for the study 11. Pregnant or lactating women 12. Inability to participate in the study (psychiatric status or psychosocial status) as assessed by the investigators.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>